Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
AssigneeFacet Biotech Corporation
InventorDaniel Afar
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating multiple myeloma comprising administering to a subject with multiple myeloma the anti-CS1 antibody HuLuc63 in combination with dexamethasone and, optionally, thalidomide.
Claims7
A method of treating multiple myeloma in a subject, the method comprising administering to a subject in need thereof (a) HuLuc63, said HuLuc63 being a humanized IgG1 antibody having a heavy chain variable region corresponding to SEQ ID NO:5 and a light chain variable region corresponding to SEQ ID NO:6, and constant regions encoded by the plasmid pHuLuc63 as deposited with the American Type Culture Collection (“ATCC”) and assigned ATCC deposit no. PTA-10989, and (b) one or more therapeutic agents, wherein said one or more therapeutic agents consist of dexamethasone and, optionally, thalidomide.
Dependencies are inferred from the claim text.